Movement Alert｜Zai Lab Falls 5.08% in Regular Trading, Partner Novocure TTFields Phase III Clinical Trial Failure Weighs on Stock

Market Focus06-22

On June 22, Zai Lab fell 5.08% in regular trading, trading at HK$13.7/share, with turnover of HK$54.50 million.

On the news front, partner Novocure announced on June 18 that its Phase III TRIDENT trial evaluating Tumor Treating Fields (TTFields) in newly diagnosed glioblastoma (GBM) failed to meet its primary overall survival (OS) endpoint. The two treatment arms showed median OS of 17.7 months and 17.5 months respectively, with HR of 0.953 and a p-value of 0.519, indicating no statistically significant benefit from earlier initiation of TTFields. Novocure's stock plunged approximately 20% on the news.

Zai Lab holds the Greater China rights to TTFields, marketed domestically under the OPTUNE brand. The product contributed approximately US$48 million in sales in 2025. While the TRIDENT trial specifically tested earlier use of TTFields rather than challenging the existing approved indication, the clinical failure raises concerns about the product's pipeline expansion value and future growth potential in Zai Lab's portfolio.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1146191369?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-22 10:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1146191369","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Zai Lab Falls 5.08% in Regular Trading, Partner Novocure TTFields Phase III Clinical Trial Failure Weighs on Stock","media":"Market Focus","content":"<p><p>On June 22, Zai Lab fell 5.08% in regular trading, trading at HK$13.7/share, with turnover of HK$54.50 million.</p><p>On the news front, partner Novocure announced on June 18 that its Phase III TRIDENT trial evaluating Tumor Treating Fields (TTFields) in newly diagnosed glioblastoma (GBM) failed to meet its primary overall survival (OS) endpoint. The two treatment arms showed median OS of 17.7 months and 17.5 months respectively, with HR of 0.953 and a p-value of 0.519, indicating no statistically significant benefit from earlier initiation of TTFields. Novocure's stock plunged approximately 20% on the news.</p><p>Zai Lab holds the Greater China rights to TTFields, marketed domestically under the OPTUNE brand. The product contributed approximately US$48 million in sales in 2025. While the TRIDENT trial specifically tested earlier use of TTFields rather than challenging the existing approved indication, the clinical failure raises concerns about the product's pipeline expansion value and future growth potential in Zai Lab's portfolio.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Zai Lab Falls 5.08% in Regular Trading, Partner Novocure TTFields Phase III Clinical Trial Failure Weighs on Stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Zai Lab Falls 5.08% in Regular Trading, Partner Novocure TTFields Phase III Clinical Trial Failure Weighs on Stock\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-22 10:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 22, Zai Lab fell 5.08% in regular trading, trading at HK$13.7/share, with turnover of HK$54.50 million.</p><p>On the news front, partner Novocure announced on June 18 that its Phase III TRIDENT trial evaluating Tumor Treating Fields (TTFields) in newly diagnosed glioblastoma (GBM) failed to meet its primary overall survival (OS) endpoint. The two treatment arms showed median OS of 17.7 months and 17.5 months respectively, with HR of 0.953 and a p-value of 0.519, indicating no statistically significant benefit from earlier initiation of TTFields. Novocure's stock plunged approximately 20% on the news.</p><p>Zai Lab holds the Greater China rights to TTFields, marketed domestically under the OPTUNE brand. The product contributed approximately US$48 million in sales in 2025. While the TRIDENT trial specifically tested earlier use of TTFields rather than challenging the existing approved indication, the clinical failure raises concerns about the product's pipeline expansion value and future growth potential in Zai Lab's portfolio.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09688","symbol_name":"再鼎医药","start_time":0,"source_url":"","article_id":"1146191369","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1146191369","pubTimestamp":1782095613,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 22, Zai Lab fell 5.08% in regular trading, trading at HK$13.7/share, with turnover of HK$54.50 million.On the news front, partner Novocure announced on June 18 that its Phase III TRIDENT...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09688":"再鼎医药"},"translate_title":"动向快讯|再鼎医药常规交易跌5.08%合作伙伴Novocure TTFields III期临床试验失败打压股价","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09688":1},"content_text":"On June 22, Zai Lab fell 5.08% in regular trading, trading at HK$13.7/share, with turnover of HK$54.50 million.On the news front, partner Novocure announced on June 18 that its Phase III TRIDENT trial evaluating Tumor Treating Fields (TTFields) in newly diagnosed glioblastoma (GBM) failed to meet its primary overall survival (OS) endpoint. The two treatment arms showed median OS of 17.7 months and 17.5 months respectively, with HR of 0.953 and a p-value of 0.519, indicating no statistically significant benefit from earlier initiation of TTFields. Novocure's stock plunged approximately 20% on the news.Zai Lab holds the Greater China rights to TTFields, marketed domestically under the OPTUNE brand. The product contributed approximately US$48 million in sales in 2025. While the TRIDENT trial specifically tested earlier use of TTFields rather than challenging the existing approved indication, the clinical failure raises concerns about the product's pipeline expansion value and future growth potential in Zai Lab's portfolio.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1146191369","isCrawlerRequest":true}